iA Global Asset Management Inc. Makes New Investment in Scholar Rock Holding Corporation $SRRK

iA Global Asset Management Inc. bought a new position in Scholar Rock Holding Corporation (NASDAQ:SRRK) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 123,272 shares of the company’s stock, valued at approximately $5,430,000.

A number of other institutional investors also recently modified their holdings of SRRK. Wellington Management Group LLP raised its stake in shares of Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after acquiring an additional 2,521,022 shares during the last quarter. Holocene Advisors LP bought a new position in shares of Scholar Rock in the third quarter worth about $91,670,000. Jennison Associates LLC raised its stake in shares of Scholar Rock by 74.0% in the fourth quarter. Jennison Associates LLC now owns 2,795,188 shares of the company’s stock worth $123,128,000 after acquiring an additional 1,188,676 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in shares of Scholar Rock in the second quarter worth about $33,062,000. Finally, UBS Group AG raised its stake in shares of Scholar Rock by 233.8% in the third quarter. UBS Group AG now owns 1,131,787 shares of the company’s stock worth $42,148,000 after acquiring an additional 792,760 shares during the last quarter. 91.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Canaccord Genuity Group assumed coverage on shares of Scholar Rock in a research report on Monday, April 20th. They set a “buy” rating and a $62.00 price target for the company. HC Wainwright lifted their price target on shares of Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Wedbush lifted their price target on shares of Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 1st. Piper Sandler lifted their price target on shares of Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 4th. Finally, Citigroup lifted their price target on shares of Scholar Rock from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Five analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $56.00.

Scholar Rock Price Performance

Shares of NASDAQ SRRK opened at $49.35 on Monday. The stock has a market cap of $5.91 billion, a P/E ratio of -13.75 and a beta of 0.70. The firm has a 50 day moving average price of $46.66 and a 200 day moving average price of $43.86. The company has a debt-to-equity ratio of 0.71, a quick ratio of 8.64 and a current ratio of 8.64. Scholar Rock Holding Corporation has a 52-week low of $27.07 and a 52-week high of $51.63.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter in the previous year, the business posted ($0.67) EPS. Analysts expect that Scholar Rock Holding Corporation will post -3.18 EPS for the current year.

Insider Activity

In related news, insider Akshay Vaishnaw sold 12,246 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $607,034.22. Following the completion of the transaction, the insider owned 630,542 shares in the company, valued at approximately $31,255,966.94. The trade was a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vikas Sinha sold 10,410 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $516,023.70. Following the transaction, the chief financial officer owned 619,856 shares of the company’s stock, valued at approximately $30,726,261.92. This represents a 1.65% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 102,736 shares of company stock valued at $4,977,900. 13.30% of the stock is currently owned by company insiders.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).